| FUSION ANTIBODIES LIMITED Patent applications |
| Patent application number | Title | Published |
|---|
| 20110243955 | ANTIBODY AND USES THEREOF - Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis | 10-06-2011 |
| 20110150886 | ANTI-AREG/HB-EGF ANTIBODIES AND TREATMENT - Described are cross-specific antibody molecules with binding specificity for both AREG and HBEGF. The antibody molecules may be used in methods of treatment of cancer and diseases associated with angiogenesis. | 06-23-2011 |
| 20110020404 | DIAGNOSTIC METHOD AND KIT - The invention relates to methods for diagnosis of tuberculosis in an animal, the methods comprising determining the presence or absence of, or an immune response to a group of antigens comprising (i) the group consisting of Rv3616 antigen, MPB70 antigen, MPB83 antigen, and ESAT 6 antigen; or (ii) at least seven of the antigens of the group consisting of Rv3616 antigen, MPB70 antigen, MPB83 antigen, ESAT 6 antigen, CFP10 antigen, α crystalline 2 antigen, PE35 antigen, and PPE68 antigen. Also provided is a method for the diagnosis of the presence of tuberculosis in a reservoir animal e.g. a badger, said method comprising determining the presence or absence of, or an immune response to Rv3616 antigen, MPB70 antigen, and MPB83 antigen. Kits for carrying out the methods are also provided. | 01-27-2011 |
| 20100111965 | COMBINATION THERAPY - The invention provides a method of treating neoplastic disease in a subject, said method comprising the simultaneous, sequential or separate, administration to said subject of an effective amount of (i) an inhibitor of a first EGF, e.g. HB-EGF and (ii) an inhibitor of a second EGF, e.g. AREG. Also described are novel synergistic combinations of EGF inhibitors with topoisomerase inhibitors which attenuate tumour cell growth. Further described are novel anti AREG antibodies. | 05-06-2010 |
| 20100086551 | ANTIBODY AND USES THEREOF - A method of inhibiting angiogenesis in a group of cells, a tissue or an organ includes administering an antibody molecule or nucleic acid encoding an antibody molecule to the cells, tissue or organ, wherein the antibody molecule specifically binds cathepsin S, but does not inhibit proteolytic activity of cathepsin S. | 04-08-2010 |
| 20090317405 | ANTIBODY AND USES THEREOF - Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis. | 12-24-2009 |
| 20090269360 | THERAPY - The invention relates to a method of inhibiting chemotherapy induced upregulation of Cathepsin S on the surface of tumour cells, the method comprising the administration of a Cathepsin S inhibitor to said cells. Also provided is a therapy comprising an anti Cathepsin S antibody, in particular an anti-Cathepsin S antibody which does not inhibit the proteolytic effect of Cathepsin S but nevertheless inhibits angiogenesis and a combination treatment comprising a Cathepsin S inhibitor and a therapeutic agent. | 10-29-2009 |
| 20090053258 | Assays for diagnosis of tuberculosis and uses thereof - The invention relates to the identification of mycobacterial antigens which are highly immunogenic and which may be used in assays and methods for the diagnosis of tuberculosis and the discrimination between infected animals and animals previously exposed to vaccines. | 02-26-2009 |
